Heterogeneity in relaxation of different sized porcine coronary arteries to nitrovasodilators: role of PKG and MYPT1

[1]  S. Erzurum,et al.  Bone Morphogenetic Protein Receptor II Is a Novel Mediator of Endothelial Nitric-oxide Synthase Activation* , 2011, The Journal of Biological Chemistry.

[2]  D. Cines,et al.  Urokinase-type Plasminogen Activator (uPA) Induces Pulmonary Microvascular Endothelial Permeability through Low Density Lipoprotein Receptor-related Protein (LRP)-dependent Activation of Endothelial Nitric-oxide Synthase* , 2011, The Journal of Biological Chemistry.

[3]  Yuan-sheng Gao,et al.  Increased degradation of MYPT1 contributes to the development of tolerance to nitric oxide in porcine pulmonary artery. , 2010, American journal of physiology. Lung cellular and molecular physiology.

[4]  Yuan-sheng Gao,et al.  The multiple actions of NO , 2010, Pflügers Archiv - European Journal of Physiology.

[5]  M. Félétou,et al.  Endothelium-derived hyperpolarising factors and associated pathways: a synopsis , 2010, Pflügers Archiv - European Journal of Physiology.

[6]  W. Schilling,et al.  Role of the cAMP/PKA signaling cascade in vasopressin‐induced trafficking of TRPC3 channels in principal cells of the collecting duct , 2010, American journal of physiology. Renal physiology.

[7]  Yuan-sheng Gao,et al.  Degradation of leucine zipper-positive isoform of MYPT1 may contribute to development of nitrate tolerance. , 2010, Cardiovascular research.

[8]  A. Friebe,et al.  The function of NO-sensitive guanylyl cyclase: what we can learn from genetic mouse models. , 2009, Nitric oxide : biology and chemistry.

[9]  H. Kwan,et al.  CNGA2 Contributes to ATP-Induced Noncapacitative Ca2+ Influx in Vascular Endothelial Cells , 2009, Journal of Vascular Research.

[10]  A. Danser,et al.  Light-induced vs. bradykinin-induced relaxation of coronary arteries: do S-nitrosothiols act as endothelium-derived hyperpolarizing factors? , 2009, Journal of hypertension.

[11]  H. Shimokawa,et al.  Endothelial dysfunction and vascular disease , 2009, Acta physiologica.

[12]  F. Brozovich,et al.  The potential role of MLC phosphatase and MAPK signalling in the pathogenesis of vascular dysfunction in heart failure , 2008, Journal of cellular and molecular medicine.

[13]  D. Dou,et al.  Protein kinase G regulates the basal tension and plays a major role in nitrovasodilator‐induced relaxation of porcine coronary veins , 2007, British journal of pharmacology.

[14]  Yuan-sheng Gao,et al.  cGMP-dependent protein kinase in regulation of basal tone and in nitroglycerin- and nitric-oxide-induced relaxation in porcine coronary artery , 2007, Pflügers Archiv - European Journal of Physiology.

[15]  Yuan-sheng Gao,et al.  Role of Rho kinases in PKG-mediated relaxation of pulmonary arteries of fetal lambs exposed to chronic high altitude hypoxia. , 2007, American journal of physiology. Lung cellular and molecular physiology.

[16]  B. Wandt,et al.  Proximal to Middle Left Coronary Artery Flow Velocity Ratio, As Assessed Using Color Doppler Echocardiography, Predicts Coronary Artery Atherosclerosis in Mice , 2006, Arteriosclerosis, thrombosis, and vascular biology.

[17]  M. Ikebe,et al.  Myosin phosphatase isoform switching in vascular smooth muscle development. , 2006, Journal of molecular and cellular cardiology.

[18]  A. Poole,et al.  Vasodilator-stimulated phosphoprotein (VASP) is phosphorylated on Ser157 by protein kinase C-dependent and -independent mechanisms in thrombin-stimulated human platelets. , 2006, The Biochemical journal.

[19]  B. Hoit,et al.  Vascular Reactivity in Heart Failure: Role of Myosin Light Chain Phosphatase , 2004, Circulation research.

[20]  D. Hartshorne,et al.  Role of Protein Phosphatase Type 1 in Contractile Functions: Myosin Phosphatase* , 2004, Journal of Biological Chemistry.

[21]  F. Brozovich,et al.  Unzipping the Role of Myosin Light Chain Phosphatase in Smooth Muscle Cell Relaxation* , 2004, Journal of Biological Chemistry.

[22]  Yu Huang,et al.  Expression of olfactory-type cyclic nucleotide-gated channel (CNGA2) in vascular tissues , 2003, Histochemistry and Cell Biology.

[23]  A. Somlyo,et al.  Ca2+ sensitivity of smooth muscle and nonmuscle myosin II: modulated by G proteins, kinases, and myosin phosphatase. , 2003, Physiological reviews.

[24]  M. Yano,et al.  Vasodilator responses of coronary conduit and resistance arteries to continuous nitroglycerin infusion in humans: a Doppler guide wire study. , 2000, Journal of cardiovascular pharmacology.

[25]  S. Narumiya,et al.  Pharmacological properties of Y-27632, a specific inhibitor of rho-associated kinases. , 2000, Molecular pharmacology.

[26]  J. Raj,et al.  Involvement of cGMP-dependent protein kinase in the relaxation of ovine pulmonary arteries to cGMP and cAMP. , 2000, Journal of applied physiology.

[27]  P. Halushka.  Thromboxane A(2) receptors: where have you gone? , 2000, Prostaglandins & other lipid mediators.

[28]  U. Walter,et al.  Analysis and Regulation of Vasodilator-stimulated Phosphoprotein Serine 239 Phosphorylation in Vitro and in Intact Cells Using a Phosphospecific Monoclonal Antibody* , 1998, The Journal of Biological Chemistry.

[29]  G. Kajiyama,et al.  Bradykinin induced dilatation of human epicardial and resistance coronary arteries in vivo: effect of inhibition of nitric oxide synthesis , 1997, Heart.

[30]  M. Sturek,et al.  Heterogeneity of L-type calcium current density in coronary smooth muscle. , 1997, The American journal of physiology.

[31]  M. Kinoshita,et al.  Heterogeneity in the vasorelaxing effect of nicorandil on dog epicardial coronary arteries: comparison with other NO donors. , 1997, Journal of cardiovascular pharmacology.

[32]  J. P. Huggins,et al.  Inhibition of cyclic GMP‐dependent protein kinase‐mediated effects by (Rp)‐8‐bromo‐PET‐cyclic GMPS , 1995, British journal of pharmacology.

[33]  J. Garthwaite,et al.  Potent and selective inhibition of nitric oxide-sensitive guanylyl cyclase by 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one. , 1995, Molecular pharmacology.

[34]  M. Biel,et al.  Primary structure and functional expression of a cyclic nucleotidegated channel from rabbit aorta , 1993, FEBS letters.

[35]  F. Cobb,et al.  Heterogeneous effects of nitroglycerin on the conductance and resistance coronary arterial vasculature. , 1993, The American journal of physiology.

[36]  M. Marcus,et al.  Mechanisms responsible for the heterogeneous coronary microvascular response to nitroglycerin. , 1991, Circulation research.

[37]  D. Harrison,et al.  Influence of vessel size on the sensitivity of porcine coronary microvessels to nitroglycerin. , 1990, The American journal of physiology.

[38]  F. Cobb,et al.  Effects of atrial natriuretic peptide on the coronary arterial vasculature in humans. , 1989, Circulation.

[39]  S. Vatner,et al.  Regulation of large coronary arteries. , 1986, Circulation research.

[40]  A. Smith,et al.  A potent synthetic peptide inhibitor of the cAMP-dependent protein kinase. , 1986, The Journal of biological chemistry.

[41]  R. A. Coleman,et al.  COMPARISON OF THE ACTIONS OF U‐46619, A PROSTAGLANDIN H2‐ANALOGUE, WITH THOSE OF PROSTAGLANDIN H2 AND THROMBOXANE A2 ON SOME ISOLATED SMOOTH MUSCLE PREPARATIONS , 1981, British journal of pharmacology.

[42]  J. Miller,et al.  Analogs of cyclic AMP and cyclic GMP: general methods of synthesis and the relationship of structure to enzymic activity. , 1974, Life sciences.

[43]  K. Node,et al.  The role of vascular failure in coronary artery spasm. , 2011, Journal of cardiology.

[44]  F. Hofmann,et al.  cGMP regulated protein kinases (cGK). , 2009, Handbook of experimental pharmacology.

[45]  J. Raj,et al.  Effect of selective phosphodiesterase inhibitors on response of ovine pulmonary arteries to prostaglandin E2. , 1998, Journal of applied physiology.

[46]  K. M. Davies,et al.  "NONOates" (1-substituted diazen-1-ium-1,2-diolates) as nitric oxide donors: convenient nitric oxide dosage forms. , 1996, Methods in enzymology.